Table 2.

Clinical trials of drugs that target other metabolic pathways than glycolysis, involved in the upregulated synthesis, proliferation, and survival of cells that have undergone metabolic rewiring.

Drug	Pathway	Disease	Trial Status	Identifier
CB-839	glutaminase	advanced solid tumor	phase I	NCT02071862
		renal cell carcinoma	phase II	NCT03428217
ADI-PEG20	arginine availability	breast cancer	phase I	NCT01948843
		hepatocellular cancer	phase II	NCT00056992
		hepatocellular cancer	phase III	NCT01287585
TVB-2640	fatty acid synthase	advanced solid tumor	phase I	NCT02223247
		NSCLC	phase II	NCT03808558
NDI-010976	acetyl-CoA carboxylase	healthy obese adults	phase I	NCT02876796
TCD-717	choline kinase	advanced solid tumor	phase I	NCT01215864
epacadostat	indoleamine-2,3-dioxygenase	solid tumor	phase I	NCT03471286
		MDS	phase II	NCT01822691
indoximod	indoleamine-2,3-dioxygenase	prostate cancer	phase II	NCT01560923
rapamycin	mTOR	thyroid cancer	phase II	NCT00936858
everolimus	mTOR	prostate cancer	phase II	NCT00976755
		kidney cancer	phase III	NCT01120249
temsirolimus	mTOR	RA	phase II	NCT00076206
leflunomide	Pyrimidine synthetase		approved
methotrexate	dihydrofolate reductase		approved
pemetrexed	dihydrofolate reductase		approved
pralatrexate	dihydrofolate reductase		approved
5-fluorouracil	thymidylate synthase		approved
S-1	thymidylate synthase		approved
pentostatin	adenosine deaminase		approved
6-mercaptopurine	adenine deaminase		approved
azathioprine	purine synthesis		approved
cladribine	adenosine deaminase		approved
gemcitabine	ribonucleotide reductase		approved
cytarabine	DNA polymerase/ribonucleotide reductase		approved
fludarabine	DNA polymerase/ribonucleotide reductase		approved
hydroxyurea	ribonucleotide reductase		approved

mTOR, mammalian target of rapamycin; NSCLC, non-small cell lung cancer; MDS, myelodysplasic syndrome.